Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Alessandro Bartoloni and Laura Maggi.
Alessandro Bartoloni
Connection Strength
0.463
Laura Maggi
  1. Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. Am J Hematol. 2021 11 01; 96(11):E408-E410.
    View in: PubMed
    Score: 0.060
  2. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. J Clin Invest. 2021 06 15; 131(12).
    View in: PubMed
    Score: 0.059
  3. Heterogeneous magnitude of immunological memory to SARS-CoV-2 in recovered individuals. Clin Transl Immunology. 2021; 10(5):e1281.
    View in: PubMed
    Score: 0.059
  4. Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab. PLoS Pathog. 2021 02; 17(2):e1009243.
    View in: PubMed
    Score: 0.058
  5. Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients. Eur J Immunol. 2020 Dec; 50(12):2013-2024.
    View in: PubMed
    Score: 0.057
  6. Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection. Immunology. 2020 12; 161(4):345-353.
    View in: PubMed
    Score: 0.057
  7. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 2020 09 01; 130(9):4694-4703.
    View in: PubMed
    Score: 0.056
  8. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia. 2021 04; 35(4):1121-1133.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.